PT  - JOURNAL ARTICLE
ED  - , 
TI  - Three Drugs Approved for Urothelial Carcinoma by FDA
AID  - 10.1158/2159-8290.CD-NB2017-071
DP  - 2017 Jul 01
TA  - Cancer Discovery
PG  - 659--660
VI  - 7
IP  - 7
4099  - http://cancerdiscovery.aacrjournals.org/content/7/7/659.short
4100  - http://cancerdiscovery.aacrjournals.org/content/7/7/659.full
SO  - Cancer Discov2017 Jul 01; 7
AB  - The FDA has approved one PD-1 checkpoint inhibitor, pembrolizumab, and two PD-L1 checkpoint inhibitors, avelumab and durvalumab, to treat metastatic urothelial carcinoma in patients whose disease continues to progress despite platinum-based chemotherapy. This brings the total number of checkpoint inhibitors for the disease to five, prompting questions about how best to use them.